Skip to main navigation Skip to search Skip to main content

VMP (Bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: Cohort analysis of the phase III VISTA study

  • Meletios A. Dimopoulos
  • , Paul G. Richardson
  • , Rudolf Schlag
  • , Nuriet K. Khuageva
  • , Ofer Shpilberg
  • , Efstathios Kastritis
  • , Martin Kropff
  • , Maria T. Petrucci
  • , Michel Delforge
  • , Julia Alexeeva
  • , Rik Schots
  • , Tamás Masszi
  • , Maria Victoria Mateos
  • , William Deraedt
  • , Kevin Liu
  • , Andrew Cakana
  • , Helgi Van De Velde
  • , Jesús F. San Miguel

Research output: Contribution to journal › Article › peer-review

159 Scopus citations

Fingerprint

Dive into the research topics of 'VMP (Bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: Cohort analysis of the phase III VISTA study'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science